Skip to content

The Role of Synovitis in Osteoarthritis

Does Synovitis Affect Treatment Efficacy in Intra-articular Injection Therapy to Osteoarthritis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03167333
Enrollment
100
Registered
2017-05-25
Start date
2020-03-01
Completion date
2020-03-01
Last updated
2020-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee, Synovitis of Knee

Brief summary

To determine whether platelet-rich-plasma (PRP) or HA (hyaluronic acid)injection into synovitis in osteoarthritis(OA) knee can achieve improvement in knee function and reduce synovitis.

Detailed description

Methods: sixty patients with OA knee having unilateral or bilateral synovitis validated by ultrasound (N=40) were studied. All the patients were randomized to receive PRP (N=40) or Hyaluronic acid(HA)(N=40) injection twice at 2-week intervals; Clinical assessments were performed using a visual analog scale(VAS) and The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) before injection at baseline, 4 weeks(first evaluation) and 12 weeks(secondary evaluation). Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.

Interventions

DRUGplatelet rich plasma

The amount of PPR was about 4-5 cc

DRUGHyaluronic acid

HA was 2.5cc

Sponsors

Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* diagnosed with OA knee according to ACR guideline 1. stiffness less than 30min 2. cracking sound during activity 3. more than 30min pain for last 2 months 4. non-bed ridden patients 5. no structure abnormality 6. synovitis was proved by US

Exclusion criteria

1\. OA knee secondary to other disease 2 . more than 10 years after diagnosing OA 3. under knee surgery within 3 months 4. autoimmune disease 5. refuses inform/consent process

Design outcomes

Primary

MeasureTime frame
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index)before injection at baseline
visual analog scale(VAS)before injection at baseline

Secondary

MeasureTime frame
Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.before injection at baseline
Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed4 weeks(first evaluation)

Countries

Taiwan

Contacts

Primary ContactChien-CHIh Wang, MD
candycandywang@gmail.com886-958738258

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026